Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Tatva Chintan Pharma Chem Total Current Liabilities Related Terms
Tatva Chintan Pharma Chem Total Current Liabilities Historical Data
* Premium members only.
The historical data trend for Tatva Chintan Pharma Chem's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tatva Chintan Pharma Chem Total Current Liabilities Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of ₹0 Mil mean?
Tatva Chintan Pharma Chem (NSE:TATVA) has a Total Current Liabilities of ₹0 Mil as of Jun. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Tatva Chintan Pharma Chem and its competitors.
Is Tatva Chintan Pharma Chem's Total Current Liabilities too high?
Tatva Chintan Pharma Chem's current Total Current Liabilities is ₹0 Mil. Overall, Tatva Chintan Pharma Chem has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tatva Chintan Pharma Chem's Total Current Liabilities compare to LIN and SHW?
Tatva Chintan Pharma Chem's Total Current Liabilities of ₹0 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Chemicals company?
A good Total Current Liabilities depends on the Chemicals industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Tatva Chintan Pharma Chem and its competitors. Tatva Chintan Pharma Chem's current Total Current Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tatva Chintan Pharma Chem stock overvalued right now?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem (NSE:TATVA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,493.31, compared to a current price of ₹1,722.40 — trading 15.3% above its estimated fair value. The current Total Current Liabilities is ₹0 Mil. Tatva Chintan Pharma Chem's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Tatva Chintan Pharma Chem (NSE:TATVA), the current Total Current Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tatva Chintan Pharma Chem (NSE:TATVA) Overvalued in 2026?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem stock appears to be overvalued.
The current stock price of ₹1,722.40 is trading 15.3% above its estimated GF Value™ of ₹1,493.31.
GuruFocus considers Tatva Chintan Pharma Chem to be Modestly Overvalued.
Key valuation signals for NSE:TATVA:
Total Current Liabilities: ₹0 Mil
GF Value™: ₹1,493.31 vs. price of ₹1,722.40 (15.3% above fair value)
No single metric tells the full story. See the NSE:TATVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacturing and selling of specialty chemicals, Pharma and Agro intermediates, Quaternary Compounds, and Quats. The company's product portfolio includes structure-directing agents, phase transfer catalysts, electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates and other specialty chemicals. The company sells its products in domestic as well as overseas markets, with the majority of revenue coming from overseas markets.
82GF Score
Get the complete analysis for NSE:TATVA
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TATVA has been successfully added to your 
